Skip to main content

Semaglutide (Investigational)


09-13-2017 | Glucagon-like peptide-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

04-04-2017 | Semaglutide (investigational) | News

SUSTAIN 2 shows better glycemic control with semaglutide than sitagliptin

The SUSTAIN 2 findings show that the glucagon-like peptide-1 analog semaglutide produces better glycemic control than the dipeptidyl peptidase-4 inhibitor sitagliptin in patients achieving inadequate control with metformin, thiazolidinediones, or both.

03-24-2017 | Semaglutide (investigational) | News

SUSTAIN 4: weekly semaglutide a good option after metformin failure

The SUSTAIN 4 findings show that a weekly semaglutide injection offers better metabolic and weight control than insulin in patients with diabetes that is poorly controlled on metformin.

Read more

Related topics